in vitro DIAGNOSTIC TECHNIQUE FOR PSEUDOALLERGEN HYPERSENSITIVITY AND SELECTING ANTIALLERGIC MEDICINES Russian patent published in 2016 - IPC G01N33/53 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to in vitro diagnostic technique for pseudoallergen hypersensitivity and selecting antiallergic medicines. That is ensured by preparing samples containing 0.95-1.05×10⁶ leukocytes, reducing them with Hanks' solution to 0.69 ml thereby producing blood samples. A test medicine is added in an amount of 0.01 ml to the produced blood samples to be incubated for 45 minutes at 37°C while stirring continuously. When testing a mixture of the medicine and pseudoallergen, the blood samples are first added with the selecting antiallergic medicine, and then incubated for 10 minutes at 37°C while stirring continuously. One portion of the produced samples is used as a test by adding a test preparation of pseudoallergen to the samples, whereas the other portion is a reference prepared by adding a pseudoallergen diluent; that is followed by one more incubation procedure for 45 minutes at 37°C. The incubated samples are separately added with the activators luminol and lucigenin in an amount of 2 mM, and a chemiluminometer is used to measure spontaneous chemiluminescence for the above activators; thereafter, the same samples are added with the luminescence stimulator barium sulphate in an amount of 2 mg/ml, and stimulated chemiluminescence is also recorded for the above activators. That is followed by calculating spontaneous and stimulated luminol- and lucigenin-dependent chemiluminescence for the test and reference preparations by formula PI = S"па"/Sk, wherein S"па"; Sk are areas under time patterns of spontaneous and stimulated chemiluminescence for the test and reference preparations respectively. The pseudoallergen hypersensitivity is diagnosed if the PI index for luminol- and lucigenin-dependent chemiluminescence is below the similar PI values specific for healthy donors. For the purpose of selecting the antiallergic medicines from tavegil, zantac and intal, the index PI* = Scl test/Scl ref is calculated; wherein: Scl test is an area under a time pattern of the luminol-dependent chemiluminescence of the sampled mixture of the antiallergic medicine and pseudoallergen; Scl ref is the same for the reference sample with the antiallergic medicine. Tavegil is likely to be prescribed if PI* is more than 1.09 in the samples with sodium metamizol; PI* is more than 1.0 in the samples with sodium salycylate and PI* is more than 1.57 in the samples with diclofenac. Zantac is prescribed if PI* is more than 1.04 in the samples with sodium metamizol; PI* is more than 0.99 in the samples with sodium salycylate and PI* is more than 1.38 in the samples with diclofenac. Intal is prescribed if PI* is more than 1.08 in the samples with sodium metamizol; PI* is more than 0.98 in the samples with sodium salycylate and PI* is more than 1.51 in the samples with diclofenac.

EFFECT: using the given technique enables the individual selection of the antiallergic medicines for treating NSAID intolerance.

7 cl, 1 dwg, 3 tbl